JP2017506257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506257A5 JP2017506257A5 JP2016558543A JP2016558543A JP2017506257A5 JP 2017506257 A5 JP2017506257 A5 JP 2017506257A5 JP 2016558543 A JP2016558543 A JP 2016558543A JP 2016558543 A JP2016558543 A JP 2016558543A JP 2017506257 A5 JP2017506257 A5 JP 2017506257A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- agx51
- substituted
- dioxol
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 230000002001 anti-metastasis Effects 0.000 claims 10
- -1 2-bromovinylamino, hydroxymethyl Chemical group 0.000 claims 9
- 230000004069 differentiation Effects 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- SRADCMOCDMFMPS-UHFFFAOYSA-N n-[3-(1,3-benzodioxol-5-yl)-3-(2-methoxyphenyl)propyl]-n-benzylpropanamide Chemical compound C=1C=CC=CC=1CN(C(=O)CC)CCC(C=1C=C2OCOC2=CC=1)C1=CC=CC=C1OC SRADCMOCDMFMPS-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000004066 vascular targeting agent Substances 0.000 claims 5
- 102000014914 Carrier Proteins Human genes 0.000 claims 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 4
- 108091008324 binding proteins Proteins 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 230000002459 sustained effect Effects 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- GCIQSQDZEOOMQQ-UHFFFAOYSA-N 2-[1-(1,3-benzodioxol-5-yl)-3-(benzylamino)propyl]phenol Chemical compound OC1=C(C=CC=C1)C(CCNCC1=CC=CC=C1)C1=CC2=C(OCO2)C=C1 GCIQSQDZEOOMQQ-UHFFFAOYSA-N 0.000 claims 1
- NEDLYQXZCPTKOD-UHFFFAOYSA-N 2-methyl-3-phenylpropanamide Chemical class NC(=O)C(C)CC1=CC=CC=C1 NEDLYQXZCPTKOD-UHFFFAOYSA-N 0.000 claims 1
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- GYJCXQBSVOOFKS-UHFFFAOYSA-N N-[3-(1,3-benzodioxol-5-yl)-3-(2-hydroxyphenyl)propyl]-N-benzylpropanamide Chemical compound CCC(=O)N(CCC(C1=CC2=C(OCO2)C=C1)C1=C(O)C=CC=C1)CC1=CC=CC=C1 GYJCXQBSVOOFKS-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 125000003435 aroyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 125000001151 peptidyl group Chemical group 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 125000002577 pseudohalo group Chemical group 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 125000005000 thioaryl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916116P | 2013-12-13 | 2013-12-13 | |
| US61/916,116 | 2013-12-13 | ||
| US201461965776P | 2014-02-06 | 2014-02-06 | |
| US61/965,776 | 2014-02-06 | ||
| PCT/US2014/070221 WO2015089495A2 (en) | 2013-12-13 | 2014-12-14 | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162598A Division JP2019203028A (ja) | 2013-12-13 | 2019-09-06 | 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017506257A JP2017506257A (ja) | 2017-03-02 |
| JP2017506257A5 true JP2017506257A5 (enExample) | 2018-02-01 |
Family
ID=53371974
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558543A Pending JP2017506257A (ja) | 2013-12-13 | 2014-12-14 | 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 |
| JP2019162598A Withdrawn JP2019203028A (ja) | 2013-12-13 | 2019-09-06 | 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162598A Withdrawn JP2019203028A (ja) | 2013-12-13 | 2019-09-06 | 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3079680A4 (enExample) |
| JP (2) | JP2017506257A (enExample) |
| CN (1) | CN107847470A (enExample) |
| AU (1) | AU2014361814A1 (enExample) |
| MX (1) | MX2016007748A (enExample) |
| WO (1) | WO2015089495A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN113106053A (zh) | 2015-04-21 | 2021-07-13 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| EP3416661A4 (en) | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
| LU100900B1 (de) * | 2018-08-10 | 2020-02-17 | Thomas Melchior Homann | Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen |
| EP3760614B8 (en) * | 2019-07-02 | 2022-04-27 | Universität Heidelberg | Chemical inhibitors of id proteins for the treatment of cancer and other diseases |
| JP2022550589A (ja) * | 2019-10-01 | 2022-12-02 | メモリアル スローン ケタリング キャンサー センター | Ｉｄタンパク質の小分子阻害剤 |
| CN113627763B (zh) * | 2021-07-30 | 2023-12-01 | 厦门大学 | 一种风险量化评估模型建立方法 |
| CN114480490A (zh) * | 2021-12-31 | 2022-05-13 | 四川省医学科学院·四川省人民医院 | 一种构建视网膜新生血管性疾病动物模型的方法 |
| CN115487358B (zh) * | 2022-08-05 | 2023-05-30 | 核工业四一六医院 | 一种用于软骨组织修复的凝胶复合支架及制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| WO2012000036A1 (en) * | 2010-06-30 | 2012-01-05 | Garvan Institute Of Medical Research | Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1 |
| US9745288B2 (en) * | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
-
2014
- 2014-12-14 WO PCT/US2014/070221 patent/WO2015089495A2/en not_active Ceased
- 2014-12-14 EP EP14870415.8A patent/EP3079680A4/en not_active Withdrawn
- 2014-12-14 AU AU2014361814A patent/AU2014361814A1/en not_active Abandoned
- 2014-12-14 CN CN201480075495.2A patent/CN107847470A/zh active Pending
- 2014-12-14 JP JP2016558543A patent/JP2017506257A/ja active Pending
- 2014-12-14 MX MX2016007748A patent/MX2016007748A/es unknown
-
2019
- 2019-09-06 JP JP2019162598A patent/JP2019203028A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506257A5 (enExample) | ||
| TWI665178B (zh) | 作為化療劑的β－取代的β－氨基酸和類似物及其應用 | |
| CN103998035B (zh) | 包含格列酮和nrf2激活剂的药物组合物 | |
| AU2016256471B2 (en) | Methods of treating cancer | |
| JP7262118B2 (ja) | 医薬組成物およびその使用 | |
| CA3018821C (en) | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas | |
| JP2016516074A5 (enExample) | ||
| BRPI1013259B1 (pt) | Moduladores lxr | |
| JP2014515407A5 (enExample) | ||
| JP2008528489A (ja) | Ｑｔ間隔調節方法 | |
| AU2019274870B2 (en) | Method of treating pain or interstitial cystitis using indole compound | |
| RS55468B1 (sr) | Jedinjenje benzotiazolona | |
| CN114025766A (zh) | 用于抑制gapdh的噁噻嗪化合物 | |
| JP7658909B2 (ja) | 筋ジストロフィー治療薬 | |
| US11389434B2 (en) | Methods and pharmaceutical compositions for the treatment of mast cell diseases | |
| JP2014505074A5 (enExample) | ||
| WO2019211783A1 (en) | Indoleamine 2,3-dioxygenase signalling modulator and therapeutic use thereof | |
| HK40067738A (en) | Oxathiazin compounds for inhibiting gapdh | |
| HK40049577A (en) | Indole compound for treating interstitial cystitis | |
| HK40049577B (en) | Indole compound for treating interstitial cystitis |